The Natural Course of Microalbuminuria among African Americans with Type 2 Diabetes: A 3-Year Study

American Journal of Medicine

Volumn 122, Issue 1, 2009, Pages 62-72

  Atta, Mohamed G ^a   Baptiste Roberts, Kesha ^b   Brancati, Frederick L ^a,b   Gary, Tiffany L ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

African Americans; Microalbuminuria; Nephropathy; Type 2 diabetes

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT; CREATINE;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC NEPHROPATHY; DISEASE COURSE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; UNIVARIATE ANALYSIS;

AFRICAN AMERICANS; AGED; ALBUMINURIA; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED;

EID: 57949084027     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2008.07.023     Document Type: Article

References (62)

1. Rostand S.G., Kirk K.A., Rutsky E.A., and Pate B.A. Racial differences in the incidence of treatment for end-stage renal disease. N Engl J Med 306 21 (1982) 1276-1279
2. Klag M.J., Whelton P.K., Randall B.L., et al. End-stage renal disease in African-American and white men. 16-year MRFIT findings. JAMA 277 16 (1997) 1293-1298
3. U.S. Renal Data System. USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Available at: http://www.usrds.org. Accessed February 6, 2008.
4. Brancati F.L., Whelton P.K., Randall B.L., et al. Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial. JAMA 278 23 (1997) 2069-2074
5. Finne P., Reunanen A., Stenman S., et al. Incidence of end-stage renal disease in patients with type 1 diabetes. JAMA 294 14 (2005) 1782-1787
6. Krakoff J., Lindsay R.S., Looker H.C., et al. Incidence of retinopathy and nephropathy in youth-onset compared with adult-onset type 2 diabetes. Diabetes Care 26 1 (2003) 76-81
7. Burrows N.R., Narva A.S., Geiss L.S., et al. End-stage renal disease due to diabetes among southwestern American Indians, 1990-2001. Diabetes Care 28 5 (2005) 1041-1044
8. Pavkov M.E., Bennett P.H., Knowler W.C., et al. Effect of youth-onset type 2 diabetes mellitus on incidence of end-stage renal disease and mortality in young and middle-aged Pima Indians. JAMA 296 4 (2006) 421-426
9. Viberti G.C., Jarrett R.J., Mahmud U., et al. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 319 8287 (1982) 1430-1432
10. Parving H.H., Oxenboll B., Svendsen P.A., et al. Early detection of patients at risk of developing diabetic nephropathy. A longitudinal study of urinary albumin excretion. Acta Endocrinologica (Copenh) 100 4 (1982) 550-555
11. Mogensen C.E. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 310 6 (1984) 356-360
12. Gall M.A., Borch-Johnsen K., Hougaard P., et al. Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 44 11 (1995) 1303-1309
13. Miettinen H., Haffner S.M., Lehto S., et al. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke 27 11 (1996) 2033-2039
14. Rossing P., Hougaard P., Borch-Johnsen K., and Parving H.-H. Predictors of mortality in insulin dependent diabetes: 10-year observational follow-up study. BMJ 313 7060 (1996) 779-784
15. Mattock M.B., Barnes D.J., Viberti G., et al. Microalbuminuria and coronary heart disease in NIDDM: an incidence study. Diabetes 47 11 (1998) 1786-1792
16. Borch-Johnsen K., Feldt-Rasmussen B., Strandgaard S., et al. Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 19 8 (1999) 1992-1997
17. Gerstein H.C., Mann J.F.E., Yi Q., et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286 4 (2001) 421-426
18. Mogensen C.E. Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes. J Intern Med 254 1 (2003) 45-66
19. Mogensen C.E., and Poulsen P.L. Microalbuminuria, glycemic control, and blood pressure predicting outcome in diabetes type 1 and type 2. Kidney Int Suppl 66 S92 (2004) S40-S41
20. Klausen K., Borch-Johnsen K., Feldt-Rasmussen B., et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 110 1 (2004) 32-35
21. de Zeeuw D., Parving H.H., and Henning R.H. Microalbuminuria as an early marker for cardiovascular disease. J Am Soc Nephrol 17 8 (2006) 2100-2105
22. Parving H.H., Lewis J.B., Ravid M., et al. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int 69 11 (2006) 2057-2063
23. Dasmahapatra A., Bale A., Raghuwanshi M.P., et al. Incipient and overt diabetic nephropathy in African Americans with NIDDM. Diabetes Care 17 4 (1994) 297-304
24. Goldschmid M.G., Domin W.S., Ziemer D.C., et al. Diabetes in urban African-Americans. II. High prevalence of microalbuminuria and nephropathy in African-Americans with diabetes. Diabetes Care 18 7 (1995) 955-961
25. Perkins B.A., Ficociello L.H., Silva K.H., Finkelstein D.M., Warram J.H., and Krolewski A.S. Regression of microalbuminuria in type 1 diabetes. N Engl J Med 348 23 (2003) 2285-2293
26. Gary T.L., Bone L.R., Hill M.N., et al. Randomized controlled trial of the effects of nurse case manager and community health worker interventions on risk factors for diabetes-related complications in urban African Americans. Prev Med 37 1 (2003) 23-32
27. Gaede P., Vedel P., Larsen N., et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 5 (2003) 383-393
28. Levey A.S., Greene T., Kusek J.W., Beck G., and MDRD Study Group. A simplified equation to predict glomerular filtration rate from serum creatinine (abstract). J Am Soc Nephrol 11 (2000) 155A
29. Olsen S., and Mogensen C.E. How often is NIDDM complicated with non-diabetic renal disease?. An analysis of renal biopsies and the literature. Diabetologia 39 12 (1996) 1638-1645
30. Warram J.H., Gearin G., Laffel L., and Krolewski A.S. Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. J Am Soc Nephrol 7 6 (1996) 930-937
31. Fioretto P., Mauer M., Brocco E., et al. Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 39 12 (1996) 1569-1576
32. Cowie C.C., Port F.K., Wolfe R.A., et al. Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. N Engl J Med 321 16 (1989) 1074-1079
33. Freedman B.I., Tuttle A.B., and Spray B.J. Familial predisposition to nephropathy in African-Americans with non-insulin-dependent diabetes mellitus. Am J Kidney Dis 25 5 (1995) 710-713
34. Seaquist E.R., Goetz F.C., Rich S., and Barbosa J. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 320 18 (1989) 1161-1165
35. Quinn M., Angelico M.C., Warram J.H., and Krolewski A.S. Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia 39 8 (1996) 940-945
36. Doria A., Lee J., Warram J.H., and Krolewski A.S. Diabetes susceptibility at IDDM2 cannot be positively mapped to the VNTR locus of the insulin gene. Diabetologia 39 5 (1996) 594-599
37. Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes 46 11 (1997) 1829-1839
38. Patrick A.W., Leslie P.J., Clarke B.F., and Frier B.M. The natural history and associations of microalbuminuria in type 2 diabetes during the first year after diagnosis. Diabet Med 7 10 (1990) 902-908
39. Remuzzi G., and Bertani T. Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules?. Kidney Int 38 3 (1990) 384-394
40. Rossing P., Hommel E., Smidt U.M., and Parving H.H. Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients. Diabetes 42 5 (1993) 715-719
41. Stehouwer C.A., Zeldenrust G.C., den Ottolander G.H., et al. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 340 8815 (1992) 319-323
42. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 3 (2000) 145-153
43. Romundstad S., Holmen J., Hallan H., et al. Microalbuminuria and all-cause mortality in treated hypertensive individuals: does sex matter?: the Nord-Trondelag Health Study (HUNT), Norway. Circulation 108 22 (2003) 2783-2789
44. Gaede P., Vedel P., Parving H.H., and Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 353 9153 (1999) 617-622
45. Shichiri M., Kishikawa H., Ohkubo Y., and Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 23 Suppl 2 (2000) B21-B29
46. Parving H.H., Lehnert H., Brochner-Mortensen J., et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345 12 (2001) 870-878
47. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 12 (2001) 861-869
48. Crook E.D., Harris J., Oliver B., et al. Endstage renal disease owing to diabetic nephropathy in Mississippi: an examination of factors influencing renal survival in a population prone to late referral. J Investig Med 49 3 (2001) 284-291
49. Ravid M., Savin H., Jutrin I., et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 118 8 (1993) 577-581
50. Schrier R.W., Estacio R.O., Esler A., and Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 61 3 (2002) 1086-1097
51. Wang P.H., Lau J., and Chalmers T.C. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 341 8856 (1993) 1306-1309
52. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 14 (1993) 977-986
53. Breyer J.A., Bain R.P., Evans J.K., et al. Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. The Collaborative Study Group. Kidney Int 50 5 (1996) 1651-1658
54. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287 19 (2002) 2563-2569
55. Gall M.A., Nielsen F.S., Smidt U.M., and Parving H.H. The course of kidney function in type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy. Diabetologia 36 10 (1993) 1071-1078
56. Ritz E., and Stefanski A. Diabetic nephropathy in type II diabetes. Am J Kidney Dis 27 2 (1996) 167-194
57. Ballard D.J., Humphrey L.L., Melton III L.J., et al. Epidemiology of persistent proteinuria in type II diabetes mellitus. Population-based study in Rochester, Minnesota. Diabetes 37 4 (1988) 405-412
58. Klein R., Klein B.E., and Moss S.E. Incidence of gross proteinuria in older-onset diabetes. A population-based perspective. Diabetes 42 3 (1993) 381-389
59. Lipton R., LaPorte R.E., Becker D.J., et al. Cyclosporin therapy for prevention and cure of IDDM. Epidemiological perspective of benefits and risks. Diabetes Care 13 7 (1990) 776-784
60. Orchard T.J., Dorman J.S., Maser R.E., et al. Factors associated with avoidance of severe complications after 25 yr of IDDM. Pittsburgh Epidemiology of Diabetes Complications Study I. Diabetes Care 13 7 (1990) 741-747
61. Krolewski A.S., Warram J.H., and Freire M.B. Epidemiology of late diabetic complications. A basis for the development and evaluation of preventive programs. Endocrinol Metab Clin North Am 25 2 (1996) 217-242
62. Ruggenenti P., Fassi A., Ilieva A.P., et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351 19 (2004) 1941-1951